A Non-interventional Study of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NEPTUN)

Trial Profile

A Non-interventional Study of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NEPTUN)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms NEPTUN
  • Most Recent Events

    • 20 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 20 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top